Telomir Pharmaceuticals Files IND for Novel Triple-Negative Breast Cancer Drug

Triple-negative breast cancer kills partly because it offers so few places to attack. Unlike hormone receptor-positive or HER2-positive subtypes, TNBC lacks the molecular targets that have driven the most meaningful advances in breast oncology over the past two decades. Into that gap, Miami-based Telomir Pharmaceuticals filed an Investigational New Drug application with the U.S. Food and Drug Administration for Telomir-1 (Telomir-Zn), its lead small-molecule candidate for advanced and metastatic TNBC.

The IND filing, announced March 31, 2026, is a regulatory gateway, not a clinical verdict. Under FDA rules, the agency has 30 days to review a new IND submission; if no clinical hold is imposed, the trial may proceed. What the FDA has reviewed is the package Telomir submitted: completed IND-enabling pharmacology, toxicology and manufacturing studies, along with a proposed Phase 1/2 protocol. What it has not yet evaluated is whether Telomir-1 works in humans. That question belongs to the trials ahead.

Telomir classifies Telomir-1 as a first-in-class metal-modulating, epigenetic therapy. The compound targets iron-dependent pathways implicated in cancer progression, an approach aligned with growing scientific interest in ferroptosis, a form of iron-driven cell death that TNBC cells appear particularly vulnerable to. In preclinical studies, the company reported antitumor effects and a favorable profile under Good Laboratory Practice safety standards, including iron-rescue experiments the company says confirm the mechanism. Telomir has submitted scientific manuscripts to peer-reviewed journals and plans to present data at the AACR Annual Meeting 2026.

Subject to FDA clearance, the planned Phase 1/2 trial will evaluate oral Telomir-1 as monotherapy in patients with advanced or metastatic TNBC, a heavily pretreated population. The trial's primary objectives will be establishing safety and tolerability in humans; secondary objectives will look for early signals of antitumor activity. Dose escalation and biomarker development will follow as the trial progresses through its phases. In parallel, Telomir said it is continuing to expand its preclinical program, evaluating Telomir-Zn in additional TNBC animal models and further characterizing its mechanism of action.

Early-stage oncology INDs carry high historical failure rates, and metal modulation as a therapeutic mechanism introduces unknowns that only first-in-human data can resolve. How the compound behaves in patients, particularly regarding tolerability at therapeutic doses, will be the defining question of the Phase 1 portion. If safety thresholds are met and early efficacy signals emerge, Telomir could pursue combination strategies pairing Telomir-1 with immune checkpoint inhibitors or chemotherapy regimens, and potentially seek discussions with regulators about accelerated development pathways.

The current standard of care for advanced TNBC has evolved, with combinations like sacituzumab govitecan plus pembrolizumab showing improved progression-free survival compared to earlier regimens. But durable responses remain elusive for many patients, particularly those who have progressed through multiple lines of therapy, underscoring why novel mechanisms continue to attract both scientific and investment attention in this space. Whether Telomir-1 can translate its preclinical iron-modulating rationale into clinical benefit will take years of rigorous testing to determine.